Yvette Mignon, MD
Internal Medicine · Tallahassee, FLNPI 1689743288
Payments from drug & device makers
Across 424 payments — averaging $51.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Novo Nordisk$744
- AstraZeneca$587
- Lilly USA, LLC$451
- Indivior Inc.$357
- Sanofi-aventis U.S. LLC$343
- plus $3K from 33 others
What the payments were for
- Consulting fees$2,10910%
- Speaking & faculty fees$12,02555%
- Travel & lodging$1,1675%
- Food & beverage$6,52930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 118 | $16,793 |
| Novo Nordisk | 58 | $744 |
| AstraZeneca | 26 | $587 |
| Lilly USA, LLC | 39 | $451 |
| Indivior Inc. | 15 | $357 |
| Sanofi-aventis U.S. LLC | 18 | $343 |
| Pfizer | 24 | $318 |
| Alkermes, Inc. | 7 | $299 |
| Bayer | 18 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $247 |
| GSK | 9 | $129 |
| Merck | 8 | $109 |
| Johnson & Johnson | 7 | $105 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $101 |
| Phathom Pharmaceuticals, Inc. | 4 | $89 |
| Abbott | 4 | $82 |
| Exact Sciences | 4 | $71 |
| Boehringer Ingelheim | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 4 | $61 |
| Amgen | 3 | $58 |
| Dexcom, Inc. | 2 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Braeburn Inc. | 2 | $41 |
| Blueprint Medicines Corporation | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Sanofi | 1 | $35 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| BETA Bionics, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Photonicare Inc | 1 | $23 |
| Radius Health, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Kvk-tech, Inc. | 4 | $17 |
| Lundbeck LLC | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,829 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $78,450 |
| EliquisApixaban | 85 | $72,668 |
| FarxigaDapagliflozin Propanediol | 46 | $49,224 |
| Dupixent SyringeDupilumab | 12 | $44,726 |
| MounjaroTirzepatide | 30 | $33,133 |
| RybelsusSemaglutide | 28 | $31,086 |
| XareltoRivaroxaban | 24 | $25,863 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $22,573 |
| LinzessLinaclotide | 32 | $22,547 |
| EntrestoSacubitril/Valsartan | 12 | $21,637 |
| OxycontinOxycodone Hcl | 19 | $20,785 |
| VraylarCariprazine Hcl | 14 | $19,230 |
| JanuviaSitagliptin Phosphate | 33 | $16,656 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 53 | $16,119 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $744 | $109,53693 claims |
| PfizerEliquis | $318 | $72,66885 claims |
| AstraZenecaFarxiga, Symbicort | $587 | $52,12659 claims |
| AbbVieLinzess, Vraylar, Synthroid | $16,793 | $43,23064 claims |
| MerckJanumet Xr, Januvia | $109 | $39,23051 claims |
| Lilly USA, LLCMounjaro | $451 | $33,13330 claims |
| Johnson & JohnsonXarelto | $105 | $25,86324 claims |
| Boehringer IngelheimCombivent Respimat | $68 | $8,76417 claims |
| GSKBreo Ellipta | $129 | $5,16612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $247 | $4,29511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Tallahassee
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.